SCHEMBL26110628

SCHEMBL26110628

Cn1c(C2=CCC3(CCNCC3)CC2)c(-c2ncc(C3CCOC3)cn2)c2c(N)ncnc21

nearest known ligand 0.30

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ RET P07949 1/20 0.30
▸ KDR P35968 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31219432 0.90 RET (0.33) RET
SCHEMBL26108236 0.85 — —
SCHEMBL30582534 0.85 NUDT14 (0.37) —
SCHEMBL26134375 0.85 NUDT14 (0.37) —
SCHEMBL30582602 0.84 DYRK1A (0.33) KDR
SCHEMBL26106237 0.84 DYRK1A (0.33) KDR
SCHEMBL30582632 0.84 SRC (0.37) RETKDR
SCHEMBL26105835 0.84 SRC (0.37) RETKDR
SCHEMBL30582547 0.83 LRRK2 (0.39) RET
SCHEMBL26108241 0.83 LRRK2 (0.39) RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4499616-A1 SPIROBICYCLIC COMPOUNDS Acerand Therapeutics (Hong Kong) Limited (HK) 2025-02-05 — — EP disclosed
CN-119013260-A Spirobicyclic compounds 优领医药科技(香港)有限公司 2024-11-22 — — CN disclosed
WO-2024091370-A1 5,6-FUSED BICYCLIC HETEROAROMATIC COMPOUNDS ACERAND THERAPEUTICS (USA) LIMITED (US) 2024-05-02 — — WO disclosed
WO-2023192502-A1 SPIROBICYCLIC COMPOUNDS ACERAND THERAPEUTICS (USA) LIMITED (US) 2023-10-05 — — WO disclosed
WO-2023192502-A1 SPIROBICYCLIC COMPOUNDS ACERAND THERAPEUTICS (USA) LIMITED (US) 2023-10-05 — — WO disclosed
Send feedback